ProMIS Neurosciences Inc. (PMN): Shareholders' Equity
-$1.26M
As of 2025-12-31
$49.40M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$1.26M | n/m | 2026-03-25, Balance as of period end |
| 2024-12-31 | $16.49M | +339.3% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $3.75M | n/m | 2025-03-31, Balance as of period end |
| 2022-12-31 | -$1.35M | n/m | 2024-04-01, Balance as of period end |
| 2021-12-31 | $5.66M | n/a | 2023-03-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | -$1.26M | n/m |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $5.29M | +28.5% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $3.15M | -20.1% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $7.01M | +82.0% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.00M | -43.3% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.59M | +2.9% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $7.52M | -34.4% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $6.16M | +125.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $6.33M | -13.5% |
Compare PMN, SNGX, INDP, ETST side by side · Screen every company in Pharmaceutical Preparations ↗